Overall Status

Recruiting (2)

Terminated (2)

Sign in for free

Phase

phase 1 (2)

phase 1/phase 2 (2)

Sponsor

Acerta Pharma BV (1)

Cyteir Therapeutics, Inc. (1)

Seagen Inc. (1)

TG Therapeutics, Inc. (1)

Collaborator

Intervention

acalabrutinib (1)

cyt-0851 (1)

cyt-0851 in combination with capecitabine (1)

cyt-0851 in combination with gemcitabine (1)

cyt-0851 in combination with rituximab and bendamustine (1)

sgn-cd19b (1)

tg-1801 (1)

ublituximab (1)

vistusertib (1)

Study Documents

Intervention Type

drug (3)

biological (1)

Funder Type

Industry (4)

Study Type

Interventional (4)

DLBCL

Showing NaN - NaN of 4

Trials per page:

STUDY

CONDITIONS

INTERVENTIONS

LOCATIONS

CLL, SLL, Richter's Transformation Trial in United States (TG-1801, Ublituximab)

Recruiting

CLL
+9 more

TG-1801
Ublituximab

Fayetteville, Arkansas
+4 more

Jan 20, 2023

Malignancy, Non-hodgkin Lymphoma, Multiple Myeloma Trial in United States (CYT-0851, CYT-0851 in combination with gemcitabine,

Recruiting

Malignancy
+14 more

CYT-0851
+3 more

Scottsdale, Arizona
+17 more

Mar 7, 2022

DLBCL, Richter Syndrome Trial in United Kingdom, United States (acalabrutinib, vistusertib)

Terminated

DLBCL
Richter Syndrome

Fairway, Kansas
+10 more

Jan 4, 2021

Non-Hodgkin Lymphoma, DLBCL, Diffuse Large B-cell Lymphoma Trial in United States (SGN-CD19B)

Terminated

Non-Hodgkin Lymphoma
+3 more

SGN-CD19B

Birmingham, Alabama
+15 more

Aug 9, 2018